Funder: ELSALYS BIOTECH

Call: (ELSALYS BIOTECH)

date_range Duration: from 11 March 2019 to 10 March 2020 (11 months) Finished
€1,304.35

Of European scope.

Evaluation of anti-CD160 antibodies in "in vivo" models.

Researchers